Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Gross Margin (2016 - 2025)

Historic Gross Margin for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to 7.89%.

  • China Pharma Holdings' Gross Margin rose 393500.0% to 7.89% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.94%, marking a year-over-year increase of 234000.0%. This contributed to the annual value of 43.84% for FY2024, which is 398300.0% down from last year.
  • According to the latest figures from Q3 2025, China Pharma Holdings' Gross Margin is 7.89%, which was up 393500.0% from 8.48% recorded in Q2 2025.
  • Over the past 5 years, China Pharma Holdings' Gross Margin peaked at 11.56% during Q1 2021, and registered a low of 109.78% during Q2 2024.
  • Over the past 5 years, China Pharma Holdings' median Gross Margin value was 10.56% (recorded in 2022), while the average stood at 13.79%.
  • In the last 5 years, China Pharma Holdings' Gross Margin tumbled by -964200bps in 2024 and then skyrocketed by 1013000bps in 2025.
  • China Pharma Holdings' Gross Margin (Quarter) stood at 10.45% in 2021, then crashed by -86bps to 1.46% in 2022, then crashed by -352bps to 3.68% in 2023, then tumbled by -285bps to 14.16% in 2024, then surged by 44bps to 7.89% in 2025.
  • Its Gross Margin was 7.89% in Q3 2025, compared to 8.48% in Q2 2025 and 11.97% in Q1 2025.